Clinical research - Press Releases

Date	Title	Company
22-Mar-2022	Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute	Biocomposites
22-Mar-2022	Envision Pharma Group and Vitaccess create a global partnership to power evidence generation for the biopharmaceutical industry	Envision Pharma Group
22-Mar-2022	SmiLe Inject invests 2 MSEK in eHealth company developing a voice robot for the elderly	SmiLe
22-Mar-2022	bioLytical Laboratories Inc. Receives its CE Mark for the iStatis COVID-19 Antigen Home Test	bioLytical Laboratories Inc
17-Mar-2022	Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer	Sanofi
16-Mar-2022	Omnix Medical Advances Novel Anti-Infective Program into Clinical Development	Omnix Medical
15-Mar-2022	Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer	Sanofi
11-Mar-2022	Emmes Acquires Casimir, Its Fourth Major Acquisition	Emmes
11-Mar-2022	How Will High Prevalence of CVD Boost Robotic Catheter Systems Market Growth?	P&S Intelligence
10-Mar-2022	Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody	Tiziana Life Sciences
10-Mar-2022	Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress	Versameb AG
08-Mar-2022	Rapid Microbial Methods, Contamination Control, Sterility Assurance and Environmental Monitoring to be covered at Microbiology East Coast Conference in Boston	SMi Group
07-Mar-2022	UK Regulator Cites CluePoints’ Solutions in Updated Guidance	CluePoints
05-Mar-2022	Exclusive Chemaxon Interview released - Sponsor at AI in Drug Discovery Conference 2022	SMi Group
28-Feb-2022	mdgroup to partner with ERGOMED on new Rare Disease Innovation Center	mdgroup
28-Feb-2022	ERGOMED announces launch of its Rare Disease Innovation Center™	ERGOMED
26-Feb-2022	STEMart Releases Subacute & Subchronic Toxicity Service for Medical Device Industry	STEMart
26-Feb-2022	CD Bioparticles Launches Ficolls to Support Bio-research	CD Bioparticles
23-Feb-2022	New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA®▼ (guselkumab) at 12 Weeks	Janssen
23-Feb-2022	Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab▼ and Golimumab Combination Therapy Versus Either Monotherapy Alone	Janssen